Residual and Recurrent Gastrointestinal Stromal Tumors With KIT Mutations: Findings at First Follow-Up CT After Imatinib Treatment

被引：3
|
作者：
Choi, Dongil [1 ,2 ]
Yoo, Eun Young [1 ,2 ]
Kim, Kyoung-Mee [3 ]
Sohn, Tae Sung [4 ]
Lee, Won Jae [1 ,2 ]
Lee, Ji Young [1 ,2 ]
Chang, Ilsoo [1 ,2 ]
机构：
[1] Sungkyunkwan Univ, Sch Med, Dept Radiol, Kangnam Ku, Seoul 135710, South Korea
[2] Sungkyunkwan Univ, Sch Med, Ctr Imaging Sci, Kangnam Ku, Seoul 135710, South Korea
[3] Sungkyunkwan Univ, Sch Med, Dept Pathol, Samsung Med Ctr, Seoul, South Korea
[4] Sungkyunkwan Univ, Sch Med, Dept Surg, Samsung Med Ctr, Seoul, South Korea
来源：
AMERICAN JOURNAL OF ROENTGENOLOGY | 2009年 / 193卷 / 02期
关键词：
cystic change; follow-up CT; gastrointestinal stromal tumor; GIST; imatinib treatment; KIT mutation; POSITRON-EMISSION-TOMOGRAPHY; TYROSINE KINASE; POOR-PROGNOSIS; CYSTIC CHANGES; MESYLATE; INHIBITION; METASTASES; RESISTANCE; DELETIONS; BIOLOGY;
D O I：
10.2214/AJR.08.2106
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OBJECTIVE. The purpose of this study was to correlate findings on the first follow-up CT after treatment with imatinib in patients with residual or recurrent gastrointestinal stromal tumors (GISTs) with the different types of KIT mutation present at initial resection. CONCLUSION. Residual and recurrent GISTs with KIT mutation of exon 11 deletion more frequently showed both tumor shrinkage and cystic change on 2-month follow-up CT images after the start of imatinib treatment than did other mutation types.
引用
收藏
页码：W100 / W105
页数：6
相关论文
共 50 条
  • [41] Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile?
    Tielen, Ronald
    Verhoef, Cornelis
    van Coevorden, Frits
    Gelderblom, Hans
    Sleijfer, Stefan
    Hartgrink, Henk H.
    Bonenkamp, Johannes J.
    van der Graaf, Winette T.
    de Wilt, Johannes H. W.
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2012, 10
  • [42] Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations
    Haller, Florian
    Detken, Sven
    Schulten, Hans-Juergen
    Happel, Nicole
    Gunawan, Bastian
    Kuhlgatz, Jens
    Fuezesi, Laszlo
    ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (02) : 526 - 532
  • [43] Combined treatment strategies in gastrointestinal stromal tumors (GISTs) after imatinib and sunitinib therapy
    Pantaleo, Maria Abbondanza
    Nannini, Margherita
    Di Battista, Monica
    Catena, Fausto
    Biasco, Guido
    CANCER TREATMENT REVIEWS, 2010, 36 (01) : 63 - 68
  • [44] Surgical Management After Neoadjuvant Imatinib Therapy in Gastrointestinal Stromal Tumours (GISTs) with Respect to Imatinib Resistance Caused by Secondary KIT Mutations
    Florian Haller
    Sven Detken
    Hans-Jürgen Schulten
    Nicole Happel
    Bastian Gunawan
    Jens Kuhlgatz
    László Füzesi
    Annals of Surgical Oncology, 2007, 14 : 526 - 532
  • [45] Clinical Significance of Pathological Complete Response in Patients with Metastatic Gastrointestinal Stromal Tumors after Imatinib Mesylate Treatment - Lessons Learned
    Cheng, Chi-Tung
    Tsai, Chun-Yi
    Yeh, Chun-Nan
    Chiang, Kun-Chun
    Chen, Yen-Yang
    Wang, Shang-Yu
    Chen, Tsung-Wen
    Tseng, Jeng-Hwei
    Jung, Shih-Ming
    Chen, Tse-Ching
    Yeh, Ta-Sen
    ANTICANCER RESEARCH, 2014, 34 (11) : 6617 - 6625
  • [46] Impact of KIT and PDGFRA Gene Mutations on Prognosis of Patients with Gastrointestinal Stromal Tumors After Complete Primary Tumor Resection
    Hou, Ying-Yong
    Grabellus, Florian
    Weber, Frank
    Zhou, Yang
    Tan, Yun-Shan
    Li, Jun
    Shen, Kun-Tang
    Qin, Jin
    Sun, Yi-Hong
    Qin, Xin-Yu
    Bockhorn, Maximillian
    Gerken, Guido
    Broelsch, Christoph E.
    Frilling, Andrea
    JOURNAL OF GASTROINTESTINAL SURGERY, 2009, 13 (09) : 1583 - 1592
  • [47] Long-term adjuvant imatinib treatment for a patient who underwent complete resection of a localized recurrent gastrointestinal stromal tumor after preoperative imatinib treatment: A case report
    Tjhoi, Welda E. H.
    Li, Kai
    Shou, Chun-hui
    Yang, Wei-li
    Yu, Ji-ren
    MEDICINE, 2019, 98 (06)
  • [48] Activating mutations in c-KIT and PDGFRα are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes
    Burger, H
    den Bakker, MA
    Kros, JM
    van Tol, H
    de Bruin, AM
    Oosterhuis, W
    van den Ingh, HFGM
    van der Harst, E
    de Schipper, HP
    Wiemer, EAC
    Nooter, K
    CANCER BIOLOGY & THERAPY, 2005, 4 (11) : 1270 - 1274
  • [49] Complete response of advanced rectal gastrointestinal stromal tumors after imatinib treatment: A case report and literature review
    Wu, Tingting
    Cheng, Xiaobin
    Chen, Wenbin
    MEDICINE, 2022, 101 (32) : E29411
  • [50] Starting Imatinib at 400 mg Daily in Patients with Gastrointestinal Stromal Tumors Harboring KIT Exon 9 Mutations: A Retrospective, Multicenter Study
    Callejo, Almudena
    Faouzi, Sara
    Bouche, Olivier
    Bertucci, Francois
    Chevalier, Thomas
    Isambert, Nicolas
    Duffaud, Florence
    Collard, Olivier
    Penel, Nicolas
    Terrier, Philippe
    Mir, Olivier
    Blay, Jean Yves
    Le Cesne, Axel
    TARGETED ONCOLOGY, 2021, 16 (04) : 485 - 492
12345